EMG
SIOX

Ellington Management Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Ellington Management Group’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,675
Closed -$188K – 863
2016
Q3 		$188K Buy
1,675
+362
+28% +$43.5K 0.05% 556
2016
Q2 		$135K Sell
1,313
-662
-34% -$66.2K 0.19% 198
2016
Q1 		$181K Buy
+1,975
New +$211K 0.08% 414

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ellington Management Group's SIOX Position: Q4 2016 in Review

Ellington Management Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2016, closing a stake of 1,675 shares — an estimated $188K sold.

Ellington Management Group first reported a position in SIOX in Q1 2016 and held it in 3 quarters. The position peaked at $188K in Q3 2016. 101 funds tracked by Wall St. Rank hold SIOX as of Q4 2016.

  • Ellington Management Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Ellington Management Group sold 1,675 Sio Gene Therapies Inc. Common Stock shares in Q4 2016, an estimated $188K.
  • Ellington Management Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2016 and held it in 3 quarters.
  • Ellington Management Group's Sio Gene Therapies Inc. Common Stock position peaked at $188K in Q3 2016.
  • 101 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2016.

Based on Ellington Management Group's 13F filing for Q4 2016, filed 14 Feb 2017.